Cancer Family
Lipomatous Neoplasm
CI-CAN-00000216Explore in graph →
Non-malignant55 active trials1 approved drugs9 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000216Explore in graph →
Clinical trials
155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01532687 | Gemcitabine With or Without Pazopanib in Treating Patients With Refractory Soft Tissue Sarcoma | completed | Phase 2 | 54 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 27, 2021 | clinicaltrials |
| NCT01913652 | Ph II Cabazitaxel DD Liposarcoma | completed | Phase 2 | 42 | European Organisation for Research and Treatment of Cancer - EORTCNETWORK | 4 | Sep 14, 2021 | clinicaltrials |
| NCT04906876 | A Phase 2 Study of 9-ING-41Combined With Chemotherapy in Adolescents and Adults With Advanced Sarcomas | withdrawn | Phase 2 | 0 | Brown UniversityOTHER | 1 | Jul 28, 2021 | clinicaltrials |
| NCT03989596 | Hypofractionated Radiotherapy With Hyperthermia in Unresectable or Marginally Resectable Soft Tissue Sarcomas(SINDIR) | unknown | Phase 2 | 30 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Feb 1, 2021 | clinicaltrials |
| NCT01876043 | Efficacy and Safety of Plitidepsin in Patients With Advanced Unresectable or Metastatic, Relapsed/Refractory, Dedifferentiated Liposarcoma (DLPS): an Exploratory Phase II Multicenter Trial(APLIPO) | terminated | Phase 2 | 24 | Institut BergoniéOTHER | 1 | Jan 25, 2021 | clinicaltrials |
| NCT03651375 | Hypofractionated Radiotherapy With Sequential Chemotherapy in Marginally Resectable Soft Tissue Sarcomas of Extremities or Trunk Wall(UN-RESARC) | unknown | Phase 2 | 46 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jan 22, 2021 | clinicaltrials |
| NCT01692496 | Activity and Tolerability of Pazopanib in Advanced and/or Metastatic Liposarcoma. A Phase II Clinical Trial | completed | Phase 2 | 52 | Grupo Espanol de Investigacion en SarcomasOTHER | 2 | Jul 23, 2020 | clinicaltrials |
| NCT02609984 | Study to Compare the Safety and Efficacy of CMB305 With Atezolizumab to Atezolizumab Alone in Participants With Sarcoma (IMDZ-C232/V943A-002) | terminated | Phase 2 | 89 | Immune Design, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jul 7, 2020 | clinicaltrials |
| NCT03397186 | Immune Changes Following Trabectedin in Patients With Metastatic or Unresectable Sarcoma | withdrawn | Phase 2 | 0 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 10, 2019 | clinicaltrials |
| NCT03816475 | Hypofractionated Radiotherapy in Locally Advanced Myxoid Liposarcomas of Extremities or Trunk Wall (LIPO-MYX Trial)(LIPOMYX) | unknown | Phase 2 | 35 | Maria Sklodowska-Curie National Research Institute of OncologyOTHER | 1 | Jun 17, 2019 | clinicaltrials |
| NCT01614795 | Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory Sarcoma | completed | Phase 2 | 46 | National Cancer Institute (NCI)NIH | 2 | Dec 11, 2018 | clinicaltrials |
| NCT01154452 | Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 1 / Phase 2 | 78 | National Cancer Institute (NCI)NIH | 1 | Aug 15, 2018 | clinicaltrials |
| NCT00659360 | AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma | completed | Phase 2 | 17 | National Cancer Institute (NCI)NIH | 2 | Jun 29, 2018 | clinicaltrials |
| NCT01653028 | Alisertib in Treating Patients With Advanced or Metastatic Sarcoma | completed | Phase 2 | 72 | National Cancer Institute (NCI)NIH | 1 | Nov 30, 2017 | clinicaltrials |
| NCT01209598 | PD0332991 (Palbociclib) in Patients With Advanced or Metastatic Liposarcoma | completed | Phase 2 | 90 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Nov 6, 2017 | clinicaltrials |
| NCT03096912 | A Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | unknown | Phase 2 | 30 | Assaf-Harofeh Medical CenterOTHER_GOV | 1 | Oct 25, 2017 | clinicaltrials |
| NCT00112463 | Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 40 | National Cancer Institute (NCI)NIH | 0 | Jun 14, 2017 | clinicaltrials |
| NCT00356031 | Bevacizumab and Radiation Therapy for Sarcomas | completed | Phase 2 | 20 | Massachusetts General HospitalOTHER | 1 | May 19, 2017 | clinicaltrials |
| NCT02249052 | Double Blind Study to Evaluate the Efficacy of Collagenase Histolyticum in the Treatment of Lipoma | completed | Phase 2 | 19 | Gerut, Zachary, M.D.INDIV | 1 | Feb 23, 2017 | clinicaltrials |
| NCT01506596 | Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Liposarcoma | completed | Phase 2 | 42 | Vector OncologyOTHER | 1 | Feb 15, 2017 | clinicaltrials |
| NCT02571829 | A Phase II Study Assessing Efficacy & Safety of Ribociclib in Patients With Advanced Well/Dedifferentiated Liposarcoma | unknown | Phase 2 | 30 | Hadassah Medical OrganizationOTHER | 1 | Nov 23, 2016 | clinicaltrials |
| NCT01613313 | A Dose Escalation Study Using Collagenase Clostridium Histolyticum in the Treatment of Lipoma | completed | Phase 2 | 14 | Zachary GerutINDIV | 1 | Oct 6, 2016 | clinicaltrials |
| NCT00608842 | Phase 2 Study for the Treatment of Superficial Lipomas | completed | Phase 2 | 62 | Kythera BiopharmaceuticalsINDUSTRY | 1 | Jan 14, 2016 | clinicaltrials |
| NCT00624416 | Association of Beta-2 Adrenergic Agonist and Corticosteroid Injection in the Treatment of Lipomas | completed | Phase 1 / Phase 2 | 10 | Pennington Biomedical Research CenterOTHER | 1 | Dec 21, 2015 | clinicaltrials |
| NCT02587169 | Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum(GEIS-27) | unknown | Phase 1 / Phase 2 | 40 | Broto, Javier Martín, M.D.INDIV | 1 | Oct 27, 2015 | clinicaltrials |
| NCT00969917 | Study Evaluating the Efficacy and Safety of IPI 504 in Patients With Advanced Dedifferentiated Liposarcoma | withdrawn | Phase 2 | 0 | Infinity Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 14, 2015 | clinicaltrials |
| NCT00233948 | Nelfinavir Mesylate in Treating Patients With Recurrent, Metastatic, or Unresectable Liposarcoma | terminated | Phase 1 / Phase 2 | 29 | City of Hope Medical CenterOTHER | 1 | Apr 1, 2015 | clinicaltrials |
| NCT00093080 | Study of AP23573/MK-8669 (Ridaforolimus), A Mammalian Target of Rapamycin (mTOR) Inhibitor, in Participants With Advanced Sarcoma (MK-8669-018 AM1)(COMPLETED) | completed | Phase 2 | 216 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Feb 13, 2015 | clinicaltrials |
| NCT00060944 | A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer | completed | Phase 2 | 271 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 8 | Sep 8, 2014 | clinicaltrials |
| NCT00579501 | Safety and Efficacy Study of Trabectedin for the Treatment of Localized Myxoid / Round Cell Liposarcoma | completed | Phase 2 | 29 | Johnson & Johnson Pharmaceutical Research & Development, L.L.C.INDUSTRY | 3 | May 7, 2014 | clinicaltrials |
| NCT00792766 | Long Term Follow Up for RAD001 Therapy of Angiomyolipomata in Patients With Tuberous Sclerosis (TSC) and Sporadic Lymphangioleiomyomatosis (LAM) | completed | Phase 1 / Phase 2 | 20 | Children's Hospital Medical Center, CincinnatiOTHER | 1 | Sep 18, 2013 | clinicaltrials |
| NCT00400569 | Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma | completed | Phase 2 | 48 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Aug 28, 2012 | clinicaltrials |
| NCT00633165 | Brostallicin Clinical Trial for Myxoid Liposarcoma(SMI-BRS-202) | unknown | Phase 2 | 24 | Systems Medicine LLCINDUSTRY | 1 | Feb 26, 2010 | clinicaltrials |
Data updated 23 days agoSource updated Sep 27, 2021source: clinicaltrials